PPARG and inflammatory bowel disease: PPARγ deactivates NF-κB, but we found no differences in NF-κB in the CLA-supplemented group, contrary to the findings of Borniquel et al. (48), who found a decrease of NF-κB in a mouse model of inflammatory bowel disease fed with CLA.